Potent, cell permeable and ATP-competitive inhibitor of DNA-PK, phosphoinositide 3-kinase (PI(3)K), the rapamycin-sensitive (mTORC1) and rapamycin-insensitive (mTORC2) complexes of the protein kinase mTOR. Exhibits little activity towards a panel of more than 40 other kinases even at concentrations as high as 10µM. Effectively blocks cell proliferation in glioma cell lines both in vitro and in vivo.
Product Details
Alternative Name: | 3-(4-(4-Morpholinyl)pyrido[3’,2’:4,5]furo[3,2-d]pyrimidin-2-yl)phenol |
|
Formula: | C19H16N4O3 |
|
MW: | 348.4 |
|
CAS: | 371935-74-9 |
|
Purity: | ≥97% (HPLC) |
|
Identity: | Identity determined by MS and NMR. |
|
Appearance: | Off-white solid. |
|
Solubility: | Soluble in DMSO (5mg/ml; warm). |
|
Shipping: | Ambient Temperature |
|
Long Term Storage: | -20°C |
|
Use/Stability: | Stock solutions are stable for up to 3 months when stored at -20°C. |
|
Handling: | Protect from light. After reconstitution, prepare aliquots and store at -20°C. |
|
Regulatory Status: | RUO - Research Use Only |
|
Please mouse over
Product Literature References
TRIM24 is an insulin-responsive regulator of P-bodies: W. Wei, et al.; Nat. Commun.
13, 3972 (2022),
Abstract;
A novel TNFR1-triggered apoptosis pathway mediated by class IA PI3Ks in neutrophils: B. Geering, et al.; Blood
117, 5953 (2011),
Abstract;
Full Text
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia: F. Chiarini, et al.; Cancer Res.
69, 3520 (2009),
Abstract;
A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma: Q.W. Fan, et al.; Cancer Cell
9, 341 (2006),
Abstract;
A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling: Z.A. Knight, et al.; Cell
125, 733 (2006),
Abstract;